Salbutamol plus beclomethasone dipropionate, but not salbutamol alone, completely prevent early and late asthmatic responses to allergen. 1991

P L Paggiaro, and F L Dente, and B Vagaggini, and E Bacci, and D Talini, and R Testi, and C E Mapp, and L M Fabbri, and C Giuntini
2nd Medical Clinic, University of Pisa, Italy.

The effect of a week treatment with inhaled salbutamol plus placebo (S+P) vs. salbutamol combined with beclomethasone dipropionate (S+BDP) on early and late asthmatic responses to inhaled allergen was studied in ten atopic patients in a randomized, double-blind, cross-over study. All patients had previously shown a dual type response to the specific bronchial provocative test (sBPT). Each patient performed two periods of treatment for a week, with a 15 day interval between them: (a) salbutamol 0.3 mg, tid + placebo; (b) salbutamol 0.3 mg+BDP 0.2 mg, tid; at the end of each treatment period, sBPT was performed and the last treatments were given 1.5-2 h before and 3-4 h after allergen challenge. S + BDP completely prevented both early and late responses to allergen, while S + P reduced but did not completely inhibit early and late responses. The difference between the two treatments was significant for early and late asthmatic responses. Non-specific bronchial hyperresponsiveness to methacholine was performed before each treatment period, after 6 days of treatment before sBPT and the day after sBPT at the end of the treatment period; there was only a mild increase in PD15FEV1 methacholine after 6 days of treatment with S + BDP in comparison with S + P treatment. These results suggest that salbutamol plus beclomethasone may be used effectively in the prophylaxis of early and late asthmatic reactions induced by allergen in sensitized subjects.

UI MeSH Term Description Entries
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001985 Bronchial Provocation Tests Tests involving inhalation of allergens (nebulized or in dust form), nebulized pharmacologically active solutions (e.g., histamine, methacholine), or control solutions, followed by assessment of respiratory function. These tests are used in the diagnosis of asthma. Allergen Bronchial Provocation Tests,Allergen Challenge, Endobronchial,Antigen Bronchial Provocation Tests,Bronchial Allergen Challenge,Bronchial Challenge Tests,Inhalation Provocation Tests,Provocation Tests, Bronchial,Endobronchial Challenge Tests,Allergen Challenge, Bronchial,Allergen Challenges, Bronchial,Allergen Challenges, Endobronchial,Bronchial Allergen Challenges,Bronchial Challenge Test,Bronchial Provocation Test,Challenge Test, Bronchial,Challenge Test, Endobronchial,Challenge Tests, Bronchial,Challenge Tests, Endobronchial,Challenge, Bronchial Allergen,Challenge, Endobronchial Allergen,Challenges, Bronchial Allergen,Challenges, Endobronchial Allergen,Endobronchial Allergen Challenge,Endobronchial Allergen Challenges,Endobronchial Challenge Test,Inhalation Provocation Test,Provocation Test, Bronchial,Provocation Test, Inhalation,Provocation Tests, Inhalation,Test, Bronchial Challenge,Test, Bronchial Provocation,Test, Endobronchial Challenge,Test, Inhalation Provocation,Tests, Bronchial Challenge,Tests, Bronchial Provocation,Tests, Endobronchial Challenge,Tests, Inhalation Provocation
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005541 Forced Expiratory Volume Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity. Forced Vital Capacity, Timed,Timed Vital Capacity,Vital Capacity, Timed,FEVt,Capacities, Timed Vital,Capacity, Timed Vital,Expiratory Volume, Forced,Expiratory Volumes, Forced,Forced Expiratory Volumes,Timed Vital Capacities,Vital Capacities, Timed,Volume, Forced Expiratory,Volumes, Forced Expiratory
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

P L Paggiaro, and F L Dente, and B Vagaggini, and E Bacci, and D Talini, and R Testi, and C E Mapp, and L M Fabbri, and C Giuntini
May 1987, The Journal of allergy and clinical immunology,
P L Paggiaro, and F L Dente, and B Vagaggini, and E Bacci, and D Talini, and R Testi, and C E Mapp, and L M Fabbri, and C Giuntini
March 1988, Annals of allergy,
P L Paggiaro, and F L Dente, and B Vagaggini, and E Bacci, and D Talini, and R Testi, and C E Mapp, and L M Fabbri, and C Giuntini
June 1995, The Journal of allergy and clinical immunology,
P L Paggiaro, and F L Dente, and B Vagaggini, and E Bacci, and D Talini, and R Testi, and C E Mapp, and L M Fabbri, and C Giuntini
February 1990, The European respiratory journal,
P L Paggiaro, and F L Dente, and B Vagaggini, and E Bacci, and D Talini, and R Testi, and C E Mapp, and L M Fabbri, and C Giuntini
November 2015, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,
P L Paggiaro, and F L Dente, and B Vagaggini, and E Bacci, and D Talini, and R Testi, and C E Mapp, and L M Fabbri, and C Giuntini
January 1993, Respiration; international review of thoracic diseases,
P L Paggiaro, and F L Dente, and B Vagaggini, and E Bacci, and D Talini, and R Testi, and C E Mapp, and L M Fabbri, and C Giuntini
July 1984, Clinical allergy,
P L Paggiaro, and F L Dente, and B Vagaggini, and E Bacci, and D Talini, and R Testi, and C E Mapp, and L M Fabbri, and C Giuntini
November 1992, The American review of respiratory disease,
P L Paggiaro, and F L Dente, and B Vagaggini, and E Bacci, and D Talini, and R Testi, and C E Mapp, and L M Fabbri, and C Giuntini
May 1984, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
P L Paggiaro, and F L Dente, and B Vagaggini, and E Bacci, and D Talini, and R Testi, and C E Mapp, and L M Fabbri, and C Giuntini
September 1984, International journal of clinical pharmacology, therapy, and toxicology,
Copied contents to your clipboard!